ReviewCNS drugs2003
Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy.
Review in CNS drugs, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Clinical review: Guide to pharmacological management in pediatric obesity medicine.Obesity pillars · 2023Review
- The Study of Carotid Artery Intima-Media Thickness in Children With Epilepsy on Anti-Epileptic Drugs.Global pediatric health · 2023Article
- The Beneficial Effect of Probiotics Supplementation on Penicillin-Induced Focal Seizure in Rats.Neurochemical research · 2022Article
- Evaluation of serum levels of asprosin and other metabolic profiles in patients with idiopathic tonic-clonic generalized epilepsy on treatment with valproic acid.European journal of clinical pharmacology · 2022Article
- Refining General Principles of Antiepileptic Drug Treatments for Epilepsy.Journal of clinical neurology (Seoul, Korea) · 2020Review
- Opportunities and challenges in the therapeutic activation of human energy expenditure and thermogenesis to manage obesity.The Journal of biological chemistry · 2020Review
- Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview.CNS drugs · 2017Review
- Rebaudioside A inhibits pentylenetetrazol-induced convulsions in rats.The Kaohsiung journal of medical sciences · 2016Article
- The long-term safety of antiepileptic drugs.CNS drugs · 2013Review
- Plasma leptin, neuropeptide Y, ghrelin, and adiponectin levels and carotid artery intima media thickness in epileptic children treated with valproate.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2012Article
- Levetiracetam: a review of its use in epilepsy.Drugs · 2011Review
- Difficulties in Treatment and Management of Epilepsy and Challenges in New Drug Development.Pharmaceuticals (Basel, Switzerland) · 2010Review
- Obesity is a common comorbidity for pediatric patients with untreated, newly diagnosed epilepsy.Neurology · 2009Article
- Review
- Spotlight on topiramate in epilepsy.CNS drugs · 2008Review
- Management of epilepsy in the elderly.Neuropsychiatric disease and treatment · 2007Article
- Levetiracetam in the treatment of childhood epilepsy.Neuropsychiatric disease and treatment · 2007Article
- Review
- Pharmacological management of neuropathic pain.CNS drugs · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The potential of specific antiepileptic drugs (AEDs) to cause clinically significant changes in bodyweight is a key consideration in the management of epilepsy; changes in weight can pose health hazards, impair body image and self-esteem, and lead to noncompliance with therapy. This article reviews the data regarding the effects of conventional and newer AEDs on weight and discusses the clinical implications of these effects for the management of patients with epilepsy. The data demonstrate that AEDs can differ substantially in their effects on weight. Some, such as valproate and carbamazepine, increase weight; others, such as topiramate and felbamate, decrease it. Still others, such as lamotrigine, levetiracetam and phenytoin, are weight neutral. Because most data regarding the effects of AEDs on weight are circumstantial, the incidence, magnitude and determinants of weight changes with AEDs remain poorly elucidated. Furthermore, little is known about the mechanisms of AED-induced changes in weight. The importance of effects on weight in selecting an AED depends largely upon the individual patient's needs and the risks and benefits of therapy for that patient. The most appropriate therapeutic choice is a weight-neutral medication unless circumstances dictate otherwise.
Indexed as
Identifiers
12921491What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.